- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
回复 tim889 的帖子
显然,您不了解同行评审的概念。 这里的读者比你更老练,他们可以对这里发布的任何论文进行判断。 你吹嘘你的背景(“结论”?)谁知道你的背景是什么,但你的行为很糟糕。 我再说一遍,这篇论文的作者都被列出来了,所以请向他们投诉,除非你觉得自己不够格。 很明显你对乙肝领域一无所知。 这里的版主是博士,是HBsAg单克隆抗体方面的专家。
Frontiers 不是一个小期刊。 2021 年,Frontiers 是被引用次数第三多的出版商。 最近发表的文章的平均引用次数从 2020 年的 4.8 次增加到 2021 年的 5.5 次。 2021年,Frontiers文章被浏览和下载5.19亿次,总计19亿次。 这比上一年增长了 64%。 文章引用量也增加了 51%,总计 380 万次引用。
Obviously, you do not understand the concept of peer review. Readers here are more sophisticated than you are, they can exercise their judgment about any papers posted here. You boasted about your background("conclusion"?) who knows what your background is, but your conduct is abysmal. I repeat, the authors of this paper are all listed, so take your complaint to them, unless you feel too unqualified to do so. It is very obvious that you are ignorant in the field of HBV. The moderator here has a PhD and is an expert in monoclonal HBsAg antibodies.
Frontiers is not a small journal. In 2021, Frontiers was the 3rd most-cited publisher. Average citations increased from 4.8 in 2020 to 5.5 in 2021 for recent articles published. In 2021, Frontiers articles were viewed and downloaded 519 million times, totalling 1.9 billion overall. This is an increase of 64% over the previous year. Article citations also increased by 51%, totalling 3.8 million citations.
|
|